New Two-Drug attack on Tough-to-Treat breast cancer
Disease control
Not yet recruiting
This study is testing whether combining two drugs, inavolisib and eribulin, can help control advanced triple-negative breast cancer that has a specific genetic change (PIK3CA mutation) and has worsened after at least one prior treatment. It will enroll about 26 patients to see ho…
Phase: PHASE2 • Sponsor: Hu Hai • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC